SCHEMBL4243315

SCHEMBL4243315

COC(=O)[C@]1(C)OC[C@@H](Cc2ccc(OCCN3c4ccccc4Sc4ccccc43)cc2)CO1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 7/20 0.44
PPARA Q07869 6/20 0.44
MAPT P10636 2/20 0.41
ALDH1A1 P00352 2/20 0.40
MEN1 O00255 1/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 1/20 0.40
KDM1A O60341 2/20 0.39
PTGS2 P35354 1/20 0.39
HDAC6 Q9UBN7 2/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4252057 1.00 PPARG (0.44) PPARGPPARAMAPTALDH1A1MEN1
SCHEMBL4250656 0.91 PPARG (0.54) PPARGPPARAMAPTALDH1A1MEN1
SCHEMBL4250655 0.91 PPARG (0.54) PPARGPPARAMAPTALDH1A1MEN1
SCHEMBL4252047 0.91 PPARG (0.54) PPARGPPARAMAPTALDH1A1MEN1
SCHEMBL4246081 0.88 PPARA (0.51) PPARGPPARAMEN1KMT2ASMPD1
SCHEMBL4249236 0.84 MAPT (0.50) PPARGPPARAMAPTALDH1A1HDAC6
SCHEMBL4252737 0.84 MAPT (0.50) PPARGPPARAMAPTALDH1A1HDAC6
SCHEMBL4248048 0.80 PPARG (0.48) PPARGPPARAMAPTALDH1A1MEN1
SCHEMBL4250721 0.80 PPARG (0.48) PPARGPPARAMAPTALDH1A1MEN1
SCHEMBL4252929 0.80 PPARG (0.55) PPARGPPARAMAPTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012069-A1 Novel Antidiabetic Compounds CADILA HEALTHCARE LIMITED (IN) 2009-01-08 US claimed
US-20090012069-A1 Novel Antidiabetic Compounds CADILA HEALTHCARE LIMITED (IN) 2009-01-08 US disclosed
EP-1781633-A1 NOVEL ANTIDIABETIC COMPOUNDS CADILA HEALTHCARE LIMITED (IN) 2007-05-09 EP disclosed
WO-2006018855-A1 NOVEL ANTIDIABETIC COMPOUNDS CADILA HEALTHCARE LIMITED (IN) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012069-A1 Novel Antidiabetic Compounds GPR119, SLC5A1, SLC5A2 PPARG 76/4885PPARA 145/4885MAPT 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.